Safety issues with bisphosphonate therapy for osteoporosis
- PMID: 23838024
- DOI: 10.1093/rheumatology/ket236
Safety issues with bisphosphonate therapy for osteoporosis
Abstract
Randomized controlled trials have demonstrated the efficacy of bisphosphonates (BP) in improving BMD and reducing fracture risk. Various safety issues that were not noted in clinical trials have, however, now emerged with post-marketing surveillance and increasing clinical experience. The risk of atypical femoral fracture could increase with long-term use of BP, although absolute risk is very small, particularly when balanced against benefits. A drug holiday should be considered after 5 years of treatment for patients at low risk of fracture, although there is no official recommendation regarding this to guide clinicians. Osteonecrosis of the jaw from low-dose BP used for osteoporosis is very rare, and mainly a complication with high-dose i.v. BP used in oncology. The risk of atrial fibrillation too is negligible, and a definite link cannot be established between BP and oesophageal cancer. BP should be avoided in patients with severe renal impairment and during pregnancy and lactation because of limited safety data. Further epidemiological and clinical data are required to establish safety of BP in long-term users (>5 years) and provide evidence-based management.
Keywords: atrial fibrillation; atypical femoral fracture; bisphosphonates; drug holiday; oesophageal cancer; osteonecrosis of jaw; osteoporosis; pregnancy; renal impairment; safety.
Similar articles
-
Long-term use of bisphosphonates in osteoporosis.J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Epub 2010 Feb 19. J Clin Endocrinol Metab. 2010. PMID: 20173017 Review.
-
Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?Clin Obstet Gynecol. 2013 Dec;56(4):743-8. doi: 10.1097/GRF.0b013e3182a98295. Clin Obstet Gynecol. 2013. PMID: 24177063 Review.
-
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.Am J Med. 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Epub 2012 Nov 20. Am J Med. 2013. PMID: 23177553 Review.
-
Safety of bisphosphonates.Rheum Dis Clin North Am. 2012 Nov;38(4):681-705. doi: 10.1016/j.rdc.2012.09.001. Rheum Dis Clin North Am. 2012. PMID: 23137577 Review.
-
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708. J Bone Miner Res. 2016. PMID: 26350171 Free PMC article. Review.
Cited by
-
The interplay of drug therapeutics and immune responses to SARS-CoV-2.Cell Mol Immunol. 2024 Feb;21(2):197-200. doi: 10.1038/s41423-023-01098-7. Epub 2023 Nov 14. Cell Mol Immunol. 2024. PMID: 37964122 Free PMC article. Review.
-
Association between bisphosphonate use and COVID-19 related outcomes.Elife. 2023 Aug 3;12:e79548. doi: 10.7554/eLife.79548. Elife. 2023. PMID: 37534876 Free PMC article.
-
Osteoporosis management by primary care physicians in Singapore: a survey on osteoporosis guidelines utilisation and barriers to care.Arch Osteoporos. 2023 May 20;18(1):72. doi: 10.1007/s11657-023-01283-1. Arch Osteoporos. 2023. PMID: 37209254 Free PMC article.
-
A Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases.Int J Mol Sci. 2022 Jul 30;23(15):8468. doi: 10.3390/ijms23158468. Int J Mol Sci. 2022. PMID: 35955603 Free PMC article. Review.
-
Oral Bisphosphonates Are Associated With Increased Risk of Severe Acute Kidney Injury in Elderly Patients With Complex Health Needs: A Self-Controlled Case Series in the United Kingdom.J Bone Miner Res. 2022 Jul;37(7):1270-1278. doi: 10.1002/jbmr.4573. Epub 2022 Jun 8. J Bone Miner Res. 2022. PMID: 35579494 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
